Phia in the News

In a perfect world, the No Surprises Act (NSA) was supposed to usher in an equitable system whereby providers and payers are able to fairly negotiate payment terms. But in reality, the ensuing dispute resolution process hasn’t been so equitable…

David Ostrowsky explores Hims & Hers’ brief attempt to introduce a low-cost, compounded alternative to Wegovy and the immediate legal backlash that forced the company to retreat. He dives into how patent protections, FDA regulations, and increased scrutiny of compounded…

David Ostrowsky examines the evolving Affordable Care Act (ACA) Marketplace landscape and what potential regulatory and political shifts could mean for employers, plan sponsors, and the broader health insurance market. He explores how changes to subsidies, enrollment policies, and plan…

In revisiting the recent class action lawsuit (Larkin v. Caremark RX, L.L.C.) against one of the country’s most prominent PBMs, CVS Caremark, David Ostrowsky explores how PBMs’ decisions favoring one medication over another due to cost differences can trigger ERISA…

This article explores the growing concern around “ghost networks,” where provider directories list physicians who are unavailable, not accepting patients, or no longer in-network. It highlights how inaccurate network data can lead to unexpected out-of-network costs for members while exposing…

Naga Vivekanandan examines the growing scrutiny of “ghost networks” — provider directories that list inaccurate or unavailable providers — and the fiduciary risks they pose for ERISA-governed health plans. She explains how inaccurate network data can expose plan sponsors to…